Acrux Limited (ASX:ACR – Get Rating) insider Donald Brumley bought 1,455,000 shares of the business's stock in a transaction dated Thursday, March 9th. The shares were purchased at an average cost of A$0.06 ($0.04) per share, with a total value of A$91,665.00 ($61,520.13).
Donald Brumley also recently made the following trade(s):
Get
Acrux alerts:
- On Wednesday, March 1st, Donald Brumley 138,187 shares of Acrux stock.
Acrux Stock Performance
The company has a quick ratio of 2.89, a current ratio of 2.55 and a debt-to-equity ratio of 33.19.
Acrux Company Profile
(Get Rating)
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone.
Featured Articles
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Acrux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrux and related companies with MarketBeat.com's FREE daily email newsletter.
Acrux Limited(ASX：ACR-GET Rating)內部人士Donald Brumley在3月9日星期四的交易中購買了該公司1,455,000股股票。這些股票是以每股0.06澳元(0.04美元)的平均成本購買的，總價值為91,665.00澳元(61,520.13美元)。
唐納德·布倫利最近還進行了以下交易：
到達
Acrux警報：
- 3月1日，星期三，唐納德·布倫利購買了138,187股Acrux股票。
Acrux股票表現
該公司的速動比率為2.89，流動比率為2.55，債務權益比為33.19。
Acrux公司簡介
(獲取評級)
Acrux有限公司及其子公司在澳大利亞、歐洲、美國和國際上開發和銷售仿製藥和局部藥物。該公司提供睪酮解決方案，如口服片劑、口腔片劑、皮下微丸、透皮貼片、注射和局部凝膠，用於治療睪丸素水準低或沒有的成年男性。
專題文章
- SVB金融崩潰對美國銀行意味著什麼
- 市場回顧周-3/6/3/10
- 2個近海鑽探公司將大賺一筆
- 未來有望實現兩位數上漲的三隻史泰博股票
- 投資者能信任消費者來提升美國戶外品牌嗎？
接受Acrux Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收Acrux和相關公司的最新新聞和分析師評級的每日簡明摘要。
